Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BioAge Labs, Inc. shareholders approved Election of three Class II Directors, Patrick Enright, James I. Healy, and Rekha Hemrajani, each to serve a three-year term at the 2026-06-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
1. The election of three Class II Directors, Patrick Enright, M.B.A., James I. Healy, M.D., Ph.D., and Rekha Hemrajani, M.B.A., each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director’s earlier resignation or removal. The vote tally was as follows: Nominees Shares For Shares Withheld Broker Non-Votes Patrick Enright, M.B.A. 30,075,928 1,184,271 5,327,405 James I. Healy, M.D., Ph.D. 25,499,205 5,760,994 5,327,405 Rekha Hemrajani, M.B.A. 27,826,781 3,433,418 5,327,405
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BioAge Labs, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-10
Exact text from the filing
2. The ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The vote tally was as follows: Shares For Shares Against Shares Abstaining 36,561,171 1,305 25,128
View on SEC.gov